Published in J Biol Chem on July 08, 1994
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A (1996) 4.49
Immunotoxins for targeted cancer therapy. AAPS J (2006) 1.86
Cytoskeletal protein ABP-280 directs the intracellular trafficking of furin and modulates proprotein processing in the endocytic pathway. J Cell Biol (1997) 1.82
A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood (2008) 1.74
A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J (2011) 1.70
The ordered and compartment-specfific autoproteolytic removal of the furin intramolecular chaperone is required for enzyme activation. J Biol Chem (2002) 1.41
Pseudomonas exotoxin-mediated selection yields cells with altered expression of low-density lipoprotein receptor-related protein. J Cell Biol (1995) 1.29
Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res (2011) 1.25
A role for PACE4 in the proteolytic activation of anthrax toxin protective antigen. Infect Immun (1997) 1.13
Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs (2009) 1.05
Retrograde transport of protein toxins through the Golgi apparatus. Histochem Cell Biol (2013) 1.03
Furin regulates both the activation of Pseudomonas exotoxin A and the Quantity of the toxin receptor expressed on target cells. Infect Immun (1996) 1.02
Toxin-based therapeutic approaches. Toxins (Basel) (2010) 1.00
Ribosome-inactivating proteins: potent poisons and molecular tools. Virulence (2013) 0.94
Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation. Proc Natl Acad Sci U S A (1996) 0.92
Aberrant hepatic processing causes removal of activation peptide and primary polymerisation site from fibrinogen Canterbury (A alpha 20 Val --> Asp). J Clin Invest (1995) 0.92
Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases. Toxins (Basel) (2012) 0.91
Topography of the hydrophilic helices of membrane-inserted diphtheria toxin T domain: TH1-TH3 as a hydrophilic tether. Biochemistry (2006) 0.85
Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity. Proc Natl Acad Sci U S A (2015) 0.83
Immunoconjugates in the management of hairy cell leukemia. Best Pract Res Clin Haematol (2015) 0.82
Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins. Biochem J (2000) 0.82
Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8. Leuk Res (2013) 0.81
Stability of mutant serpin/furin complexes: dependence on pH and regulation at the deacylation step. Protein Sci (2005) 0.80
Towards Engineering Novel PE-Based Immunotoxins by Targeting Them to the Nucleus. Toxins (Basel) (2016) 0.79
Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A. Breast Cancer Res Treat (2005) 0.79
Elevation of vacuolar pH inhibits the cytotoxic activity of furin-cleaved exotoxin A. Infect Immun (1997) 0.78
Efficiency of immunotoxin cytotoxicity is modulated by the intracellular itinerary. PLoS One (2012) 0.78
The Molecular Basis of Toxins' Interactions with Intracellular Signaling via Discrete Portals. Toxins (Basel) (2017) 0.75
The Father, Son and Cholix Toxin: The Third Member of the DT Group Mono-ADP-Ribosyltransferase Toxin Family. Toxins (Basel) (2015) 0.75
Clinical targeting recombinant immunotoxins for cancer therapy. Onco Targets Ther (2017) 0.75
Adenovirus-induced release of epidermal growth factor and pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis. Cell (1983) 2.74
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med (2001) 2.65
Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature (1988) 2.55
The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem (1992) 2.40
Small RNA regulators and the bacterial response to stress. Cold Spring Harb Symp Quant Biol (2006) 2.31
A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature (1989) 2.13
Recombinant toxins as novel therapeutic agents. Annu Rev Biochem (1992) 2.05
Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. J Biol Chem (1990) 2.04
B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci U S A (1991) 1.89
Immunotoxins. Cell (1986) 1.82
Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. J Biol Chem (1989) 1.54
Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin. Proc Natl Acad Sci U S A (1987) 1.48
Dissection of receptor folding and ligand-binding property with functional minireceptors of LDL receptor-related protein. J Cell Sci (2001) 1.48
CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses. Proc Natl Acad Sci U S A (1989) 1.44
Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol. J Biol Chem (1992) 1.38
Mutational analysis of domain I of Pseudomonas exotoxin. Mutations in domain I of Pseudomonas exotoxin which reduce cell binding and animal toxicity. J Biol Chem (1988) 1.35
Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Int J Cancer (1999) 1.34
Proteases from human immunodeficiency virus and avian myeloblastosis virus show distinct specificities in hydrolysis of multidomain protein substrates. J Virol (1990) 1.33
Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res (2000) 1.33
The 39-kDa receptor-associated protein regulates ligand binding by the very low density lipoprotein receptor. J Biol Chem (1994) 1.30
Pseudomonas exotoxin-mediated selection yields cells with altered expression of low-density lipoprotein receptor-related protein. J Cell Biol (1995) 1.29
Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood (1997) 1.24
A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc Natl Acad Sci U S A (1987) 1.21
Furin-mediated cleavage of Pseudomonas exotoxin-derived chimeric toxins. J Biol Chem (1997) 1.21
Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res (1990) 1.20
A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins. Proc Natl Acad Sci U S A (1990) 1.20
Isolation of tumor cell growth-inhibiting factors from a human rhabdomyosarcoma cell line. Cancer Res (1985) 1.20
Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin. Proc Natl Acad Sci U S A (1989) 1.19
Pseudomonas exotoxin-anti-TAC. Cell-specific immunotoxin active against cells expressing the human T cell growth factor receptor. J Clin Invest (1984) 1.13
Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines. Cancer Res (1985) 1.12
Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxin. Proc Natl Acad Sci U S A (1991) 1.12
Barnase toxin: a new chimeric toxin composed of pseudomonas exotoxin A and barnase. Cell (1991) 1.11
Enhancement of toxicity of antitransferrin receptor antibody-Pseudomonas exotoxin conjugates by adenovirus. Proc Natl Acad Sci U S A (1983) 1.09
Pseudomonas exotoxin coupled to a monoclonal antibody against ovarian cancer inhibits the growth of human ovarian cancer cells in a mouse model. Proc Natl Acad Sci U S A (1987) 1.08
Reduction of furin-nicked Pseudomonas exotoxin A: an unfolding story. Biochemistry (1999) 1.07
Two distinct tumor cell growth-inhibiting factors from a human rhabdomyosarcoma cell line. Cancer Res (1985) 1.05
Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors. Proc Natl Acad Sci U S A (1990) 1.03
Interdomain hydrolysis of a truncated Pseudomonas exotoxin by the human immunodeficiency virus-1 protease. J Biol Chem (1990) 1.03
Antitumor effects of an immunotoxin made with Pseudomonas exotoxin in a nude mouse model of human ovarian cancer. Proc Natl Acad Sci U S A (1986) 1.01
Antitumor activity of a transforming growth factor alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE40). Cancer Res (1991) 0.97
Translocation mediated by domain II of Pseudomonas exotoxin A: transport of barnase into the cytosol. Biochemistry (1992) 0.97
Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys. Cancer Res (1992) 0.96
Mechanism of action of Pseudomonas exotoxin. Identification of a rate-limiting step. J Biol Chem (1993) 0.96
A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin. Proc Natl Acad Sci U S A (1990) 0.96
Mutation at the processing site of chicken low density lipoprotein receptor-related protein impairs efficient endoplasmic reticulum exit, but proteolytic cleavage is not essential for its endocytic functions. J Biol Chem (1998) 0.96
8-Epi PGF2 alpha: specific analysis of an isoeicosanoid as an index of oxidant stress in vivo. Br J Clin Pharmacol (1996) 0.95
Characterization of immunotoxins active against ovarian cancer cell lines. J Clin Invest (1985) 0.95
Cytotoxic activity of an interleukin 6-Pseudomonas exotoxin fusion protein on human myeloma cells. Proc Natl Acad Sci U S A (1988) 0.95
Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice. Cancer Res (1990) 0.94
Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds. Bioconjug Chem (1995) 0.94
The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia. Proc Natl Acad Sci U S A (1990) 0.91
Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity. Cancer Res (1993) 0.88
Interleukin 2 (IL2) PE40 is cytotoxic to cells displaying either the p55 or p70 subunit of the IL2 receptor. J Biol Chem (1988) 0.86
Cytotoxic activity of a recombinant fusion protein between interleukin 4 and Pseudomonas exotoxin. Proc Natl Acad Sci U S A (1989) 0.86
Alteration of a protease-sensitive region of Pseudomonas exotoxin prolongs its survival in the circulation of mice. Proc Natl Acad Sci U S A (1992) 0.85
Selective killing of tumor cells using EGF or TGF alpha-Pseudomonas exotoxin chimeric molecules. Semin Cancer Biol (1990) 0.85
Characterization of V3 loop-Pseudomonas exotoxin chimeras. Candidate vaccines for human immunodeficiency virus-1. J Biol Chem (1998) 0.85
Mucosal administration of a chimera composed of Pseudomonas exotoxin and the gp120 V3 loop sequence of HIV-1 induces both salivary and serum antibody responses. Vaccine (1999) 0.85
Five-year clinical experience with Abiomed BVS 5000 as a ventricular assist device for cardiac failure. Perfusion (2001) 0.85
Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies. Bioconjug Chem (1997) 0.84
Chemoimmunotoxin therapy against a human colon tumor (HT-29) xenografted into nude mice. Cancer Res (1989) 0.84
Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice. Cancer Res (1993) 0.83
A recombinant form of Pseudomonas exotoxin A containing transforming growth factor alpha near its carboxyl terminus for the treatment of bladder cancer. J Urol (1993) 0.83
Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor alpha at different locations in Pseudomonas exotoxin. Bioconjug Chem (1992) 0.83
Enhancement of the activity of immunotoxins by analogues of verapamil. Cancer Res (1989) 0.82
Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer. Cancer Res (1987) 0.82
Cardiac allograft survival in mice treated with IL-2-PE40. Proc Natl Acad Sci U S A (1989) 0.82
Transforming growth factor alpha-Pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts. Proc Natl Acad Sci U S A (1990) 0.82
Pseudomonas exotoxin--immunotoxins. Cancer Treat Res (1988) 0.82
Selection of Pseudomonas exotoxin-resistant cells with altered expression of alpha 2MR/LRP. Ann N Y Acad Sci (1994) 0.82
Divergent Pseudomonas exotoxin A sensitivity in normal and transformed liver cells is correlated with low-density lipoprotein receptor-related protein expression. Toxicon (2001) 0.82
Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells. Biochem Soc Trans (1997) 0.81
Antitumor effects of interleukin 6-Pseudomonas exotoxin chimeric molecules against the human hepatocellular carcinoma, PLC/PRF/5 in mice. Cancer Res (1991) 0.81
Pseudomonas exotoxin exhibits increased sensitivity to furin when sequences at the cleavage site are mutated to resemble the arginine-rich loop of diphtheria toxin. Mol Microbiol (1996) 0.81
Polyethylene glycol-modified chimeric toxin composed of transforming growth factor alpha and Pseudomonas exotoxin. Cancer Res (1993) 0.80
Cytotoxicity of IL6-PE40 and derivatives on tumor cells expressing a range of interleukin 6 receptor levels. J Biol Chem (1990) 0.80
Analysis of sequences in domain II of Pseudomonas exotoxin A which mediate translocation. Biochemistry (1991) 0.80
Rational design of a chimeric toxin: an intramolecular location for the insertion of transforming growth factor alpha within Pseudomonas exotoxin as a targeting ligand. Bioconjug Chem (1992) 0.79
A proper amino terminus of diphtheria toxin is important for cytotoxicity. Biochem Biophys Res Commun (1991) 0.79
Generation of a potent chimeric toxin by replacement of domain III of Pseudomonas exotoxin with ricin A chain KDEL. Bioconjug Chem (1996) 0.79
Human A673 cells secrete high molecular weight EGF-receptor binding growth factors that appear to be immunologically unrelated to EGF or TGF-alpha. J Cell Biochem (1986) 0.78
Cytotoxic activity of a recombinant fusion protein between insulin-like growth factor I and Pseudomonas exotoxin. Cancer Res (1991) 0.78
Expression of hepatocyte low-density lipoprotein receptor-related protein is post-transcriptionally regulated by extracellular matrix. Lab Invest (1998) 0.78
IL2-PE664Glu, a new chimeric protein cytotoxic to human-activated T lymphocytes. J Biol Chem (1990) 0.77
Use of Pseudomonas aeruginosa toxin A in the construction of conjugate vaccines and immunotoxins. Rev Infect Dis (1988) 0.77
Enhanced macrophage resistance to Pseudomonas exotoxin A is correlated with decreased expression of the low-density lipoprotein receptor-related protein. Infect Immun (1999) 0.77
Epithelial application of Pseudomonas aeruginosa exotoxin A results in a selective targeting to cells in the liver, spleen and lymph node. J Control Release (2000) 0.77
Cell-specific toxicity of a chimeric protein composed of interleukin-6 and Pseudomonas exotoxin (IL6-PE40) on tumor cells. Mol Cell Biol (1990) 0.77
Interleukin-6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma. Blood (1992) 0.77
Enhancement of the activity of immunotoxins made with either ricin A chain or Pseudomonas exotoxin in human ovarian and epidermoid carcinoma cell lines. Cancer Res (1988) 0.76
Treatment of acute myelocytic leukemia with interleukin-6 Pseudomonas exotoxin fusion protein in a rat leukemia model. Leukemia (1996) 0.76
Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia. Leukemia (1993) 0.76
Ligand-toxin hybrids directed to the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein exhibit lower toxicity than native Pseudomonas exotoxin. J Biol Chem (1996) 0.76
Enhancement of the cytotoxic effect of anti-carcinoembryonic antigen immunotoxins by adenovirus and carboxylic ionophores. J Natl Cancer Inst (1987) 0.76
GM-CSF receptor targeted treatment of primary AML in SCID mice using Diphtheria toxin fused to huGM-CSF. Leukemia (1998) 0.76